Naltrexone for the management of alcohol dependence

New England Journal of Medicine

Volumn 359, Issue 7, 2008, Pages 715-

  Anton, Raymond F ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BISMUTH SALICYLATE; DISULFIRAM; NALTREXONE; TOPIRAMATE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISEASE; ABDOMINAL PAIN; ALCOHOL CONSUMPTION; ALCOHOLISM; ANAMNESIS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRINKING BEHAVIOR; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ASSAY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE PERSONNEL; HUMAN; LABORATORY TEST; LIVER TOXICITY; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; ALCOHOLISM; COMBINED MODALITY THERAPY; DOPAMINE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC;

EID: 49449100226     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct0801733     Document Type: Article

References (49)

1. Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: national findings. NSDUH series H-32. Rockville, MD: Office of Applied Studies, 2007. (DHHS publication no. SMA 07-4293.)
2. Global status report: alcohol policy. Geneva: World Health Organization, 2004.
3. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism, 2000.
4. Fiellin DA, Carrington R, O'Connor PG. New therapies for alcohol problems: application to primary care. Am J Med 2000;108:227-37.
5. Lowenfels AB, Miller TT. Alcohol and trauma. Ann Emerg Med 1984;13:1056-60.
6. Klatsky AL. Alcohol-associated hypertension: when one drink makes a difference. Hypertension 2004;44:805-6.
7. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007;64:830-42.
8. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004;74:223-34.
9. Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998;22:3-9.
10. Myrick H, Anton RF, Li X, et al. Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology 2004;29:393-402.
11. 2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 2004;161:1783-9. [Erratum, Am J Psychiatry 2004;161:2344.]
12. Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993;621:137-40.
13. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 1998;18:10663-71.
14. Middaugh LD, Szumlinski KK, Van Patten Y, Marlowe AL, Kalivas PW. Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its interoceptive cues and increases extracellular dopamine, an effect blocked by naltrexone. Alcohol Clin Exp Res 2003;27:1892-900.
15. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 2008;65:466-75.
16. Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 2004;28:1362-70.
17. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) 2002;160:19-29.
18. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) 2004;173:32-40.
19. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001;345:1734-9.
20. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295:2003-17.
21. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001;36:544-52.
22. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001;25:1335-41.
23. Bouza C, Angeles M, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004;99:811-28. [Erratum, Addiction 2005;100:573.]
24. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005;8:267-80.
25. Idem. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005;1:CD001867.
26. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005;293:1617-25. [Errata, JAMA 2005;293:1978, 2864.]
27. Pettinati HM, Volpicelli JR, Pierce JD Jr, O'Brien CP. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 2000;19:71-83.
28. O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007;27:507-12.
29. Miller WR, Wilbourne PL. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 2002;97:265-77.
30. Carroll KM. Integrating psychotherapy and pharmacotherapy to improve drug abuse outcomes. Addict Behav 1997;22:233-45.
31. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007;298:1641-51.
32. Johnson BA, Rosenthal N, Capece JA, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 2008;168:1188-99.
33. Miller PM, Ornstein SM, Nietert PJ, Anton RF. Self-report and biomarker alcohol screening by primary care physicians: the need to translate research into guidelines. Alcohol Alcohol 2004;39:325-8.
34. Miller PM, Anton R. Biochemical alcohol screening in primary health care. Addict Behav 2004;29:1427-37.
35. Fleming M, Mundt M. Carbohydrate-deficient transferrin: validity of a new alcohol biomarker in a sample of patients with diabetes and hypertension. J Am Board Fam Pract 2004;17:247-55.
36. Medical management (MM) treatment manual. COMBINE monograph series. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism, 2004. (DHHS publication no. (NIH) 04-5289.)
37. Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl 2005;15:170-8.
38. Williams SH. Medications for treating alcohol dependence. Am Fam Physician 2005;72:1775-80.
39. New drug bulletin: naltrexone extended-release suspension for injection. Salt Lake City: Department of Pharmacy Services, University of Utah Hospital, 2007. (Accessed July 21, 2008, at http://uuhsc.utah. edu/pharmacy/bulletins/ NDB_126.pdf.)
40. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Arch Gen Psychiatry 1997;54:1130-5.
41. Practice guideline for the treatment of patients with substance use disorders. 2nd ed. Am J Psychiatry 2007;164:Suppl: A5-A124. (Also available at http://ajp.psychiatryonline.org/cgi/data/164/4/A58/DC2/1.)
42. O'Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996;53:217-24.
43. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999;156:1758-64.
44. Donovan DM, Anton RF, Miller WR, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE Study): examination of posttreatment drinking outcomes. J Stud Alcohol Drugs 2008;69:5-13.
45. Anton RF, Moak DH, Latham PK, et al. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 2001;21:72-7.
46. Berglund M, Thelander S, Salaspuro M, Franck J, Andréasson S, Ojehagen A. Treatment of alcohol abuse: an evidence-based review. Alcohol Clin Exp Res 2003;27:1645-56.
47. O'Malley SS, Rounsaville BJ, Farren C, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med 2003;163:1695-704.
48. Treatment Improvement Protocol (TIP) series. Rockville, MD: Department of Health and Human Services, 1998. (Accessed July 21, 2008, at http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5. chapter.51510.)
49. Helping patients who drink too much: a clinician's guide: updated 2005 edition. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism, 2007. (Accessed July 21, 2008, at http://pubs.niaaa.nih.gov/publications/ Practitioner/CliniciansGuide2005/guide.pdf.)